Lilly's next-gen drug tops Zepbound on weight loss in late-stage osteoarthritis trial
Eli Lilly's retatrutide delivered 28.7% average weight loss in late-stage trials, surpassing its blockbuster Zepbound and analyst expectations, reinforcing the company's dominance in the obesity drug market.
Insights:
Eli Lilly announced on Thursday that its next-generation obesity drug retatrutide helped patients lose an average of 28.7% of their weight in a late-stage trial, significantly outperforming its blockbuster drug Zepbound and reinforcing the company's leadership position in the rapidly expanding obesity treatment market.
